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tNoninvasive prenatal diagnosis using cell-free fetal DNAin the maternal plasma is moving into routine clinical
practice for some indications. Here we discuss exciting devel-
opments in noninvasive prenatal diagnosis for aneuploidy af-
forded by recent publications, including 2 papers published in
this journal, and highlight some of the issues that need to be
considered before these tests can be implemented as part of
routine antenatal care.
Finally, after years of hunting for the elusive fetal cells in the
maternal circulation to use for genetic prenatal diagnosis,1 it
seems that cell-free fetal DNA (cffDNA)will provide the basis for
a safer, noninvasive approach to prenatal diagnosis. Since the
identification of cffDNA in maternal plasma in the late 1990s,2
there has been much research on how cffDNA can be used as an
alternative to invasive tests to provide safer, yet robust, noninva-
sive prenatal diagnosis (NIPD) for families at high risk of genetic
disorders and for other pregnancy complications such as hemo-
lytic disease of the newborn and fetal aneuploidy. In recent
months we have seen the publication of papers describing imple-
mentation of this technology into routine obstetric practice to
directadministrationofanti-DforallRhD-negativemothers3and
aspartof standardgenetic care todetermine fetal sex forwomenat
high risk of sex-linked disorders. The clinical utility of NIPD in
reducing the need for invasive testing4-6 and favorable costs have
een clearly demonstrated.7
There have been a variety of approaches to the noninvasive
diagnosis of aneuploidy reported (Table 1), culminating in the
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good sensitivities and specificities for the detection of trisomy
21 using next-generation sequencing.8,9 Such is the volume of
ork generated over recent years that we are now seeing the
ublication of systematic reviews describing the application of
IPD for both fetal sex determination10 and aneuploidy diag-
nosis.11 In this issue, we see 2 papers published describing an
lternative sequencing approach to NIPD for aneuploidy that
mploys targeted, or chromosome-selective, sequencing that
ppears to be highly accurate and potentially more cost-effec-
ive than previously reported sequencing approaches.
Given that technological advances are bringing noninvasive
esting for aneuploidy ever closer, here we aim to initiate dis-
ussions on how implementationmight proceed. In the course
f developing the arguments we have made several assump-
ions, which may or may not be born out in practice when
arger studies are published. Specifically, will/should it be non-
nvasive prenatal diagnosis or should it be an extension of non-
nvasive prenatal screening;12 will this new service be delivered
universally across the developed world; how will current prac-
tices influence service delivery; what are the cost implications,
what do consumers think, and how should we incorporate
their views; and finally, will it be necessary or possible to regu-
late the provision of NIPD by commercial companies?
The 2 papers published in this issue describe the use of mas-
sively parallel sequencing for NIPD of trisomies 18 and 21 us-
ing assays targeted to nonpolymorphic loci on chromosomes
18 and 21. The first stage of this work, reported elsewhere,13
described the development of a multiplex assay, termed “digi-
tal analysis of selected regions,” comprising targets on chromo-
somes 18 and 21. In the first of the papers reported in this
journal, digital analysis of selected regions is used to develop an
algorithm, fetal-fraction optimized risk of trisomy (FORTE),
which uses the proportion of specific cffDNA in the samples,
estimated by targeting additional sequences not usually in-
volved in aneuploidy, and the prior risk of trisomy (taken from
published data on maternal and fetal gestational age related
risks) to estimate the risk of trisomies 18 and 21.14 The authors
hen describe its application in 2 cohorts; the first cohort was
sed to develop quality-control parameters, and the second to
valuate performance in a blinded, small group of samples. In
he second study by Ashoor et al,15 400 samples from pregnan-
cies with knownkaryotypes, 300 fromeuploid pregnancies and
50 each from pregnancies affected by trisomy 18 and 21, were
analyzed by Sparks’ laboratory to give an estimate of risk for
trisomy18 and21. Bothpapers report highdegrees of accuracy,
with the second paper reporting correct identification of all
trisomy 21 fetuses, 98% of those with trisomy 18 having all
euploid fetuses correctly identified, and a very low (1%) assay
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they take other risk factors into account to give a risk of an
individual fetus being affected. In so doing, they may well im-
prove accuracy. Although the data reported here pertain to
high-risk pregnancies, they are clearly aiming to deliver their
test to the low-risk population as a highly accurate screening
test for Down syndrome (DS) and other aneuploidies, as evi-
denced by the recent press release in which they launch a mul-
ticenter study of 25,000 pregnancies with the objective of com-
paring FORTE with current combined screening for DS.30
Screening or diagnosis?
That brings to the fore the issue of towhomand how these tests
should be offered. Should it be to all women in early pregnancy
TABLE 1
Summary of studies reporting detection of fetal aneup
using variety of methods of noninvasive prenatal diagn
Study Method
Total no.
samples
tested
No. normal
tested (true
negatives)
Lo et al16 RNA allelic ratio 67 57 (55)
....................................................................................................................................................................................
Tsui et al17 RNA allelic ratio 62 58 (51)
....................................................................................................................................................................................
Fan et al18,19 MPS 18 T21 cohort:
T18 cohort:
T13 cohort:
....................................................................................................................................................................................
Chiu et al20 MPS 28 14 (14)
....................................................................................................................................................................................
Ghanta et al21 Tandem SNP 27 20 (20)
....................................................................................................................................................................................
Tong et al22 Differential methylation 29 24 (23)
....................................................................................................................................................................................
Papageorgiou et al23 Differential methylation 40 26 (26)
....................................................................................................................................................................................
Deng et al24 RT-MLPA 113 87 (87)
....................................................................................................................................................................................
Chiu et al25 MPS 15 10 (10)
....................................................................................................................................................................................
Sehnert et al26 MPS 47 T21 cohort:
T18 cohort:
T13 cohort:
....................................................................................................................................................................................
Chen et al27 MPS (2 plex) 289 T13 cohort:
T18 cohort:
....................................................................................................................................................................................
Ehrich et al28 MPS (4 plex) 449 410 (409)
....................................................................................................................................................................................
Lau et al29 MPS (12 plex) 108 T21 cohort:
T18 cohort:
T13 cohort:
....................................................................................................................................................................................
Chiu et al8 MPS (8 plex) 657 571 (6)
....................................................................................................................................................................................
Chiu et al8 MPS (2 plex) 232 146 (3)
....................................................................................................................................................................................
Palomaki et al9 MPS 1683 1471 (1468)
....................................................................................................................................................................................
Sparks et al14 Targeted MPS 167 123 (123)
....................................................................................................................................................................................
Ashoor et al15 Targeted MPS 397 297 (297)
....................................................................................................................................................................................
CI, confidence interval; MLPA, multiplex ligation-dependent probe amplification; MPS, massively
aAll CIs have been calculated by one of the authors (H.W.) using data published in the articles qu
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270 American Journal of Obstetrics& Gynecology APRIL 2012sive diagnostic testing in those women identified as being at
high risk following current screening–ie, as a sequential test?31
Many factors will influence the answer to these questions: not
just accuracy, but turnaround time, scalability, and cost. The
latter will no doubt feature prominently in these times of eco-
nomic hardship. But do we need to offer these new tests to all
women, and should we do so anyway?
In theUnitedKingdom,many other parts of Europe, and the
United States, government policy is that all women should be
offered DS screening and/or diagnosis.32,33 Increasingly, DS
creening is delivered by the first-trimester combined test,
hich is predicated on a combination of fetal ultrasound (to
onfirm gestation, the number of fetuses present and to assess
he nuchal translucency measurement), and the levels of ma-
y
is
ples
No. aneuploid
samples
tested (true
positive)
Sensitivity, %
(95% CI)a
Specificity, %
(95% CI)a
10 (9) 90 (60.6–99.5) 96.5 (89.4–99.4)
...................................................................................................................................................................................
4 (4) 100 (47.3–100) 89.7 (80.6–95.4)
...................................................................................................................................................................................
)
16)
17)
T21: 9 (9)
T18: 2 (2)
T13: 1 (1)
T21: 100 (71.8–100)
T18: 100 (22.4–100)
T13: 100 (5–100)
T21: 100 (71.8–100)
T18: 100 (82.9–100)
T13: 100 (83.8–100)
...................................................................................................................................................................................
14 (14) 100 (80.7–100) 100 (80.7–100)
...................................................................................................................................................................................
7 (7) 100 (65.2–100) 100 (86.1–100)
...................................................................................................................................................................................
5 (5) 100 (55–100) 95.8 (81.7–99.8)
...................................................................................................................................................................................
14 (14) 100 (80.7–100) 100 (89.2–100)
...................................................................................................................................................................................
25 (23) 92 (77–98.6) 100 (96.6–100)
...................................................................................................................................................................................
5 (5) 100 (54.9–100) 100 (74.2–100)
...................................................................................................................................................................................
34)
39)
46)
T21: 13 (13)
T18: 8 (8)
T13: 1 (no call)
T21: 100 (79.5–100)
T18: 100 (68.8–100)
T13: –
T21: 100 (91.6–100)
T18: 100 (92.6–100)
T13: 100 (93.7–100)
...................................................................................................................................................................................
(261)
(248)
T18: 37 (34)
T13: 25 (25)
T18: 91.9 (80.4–97.8)
T13: 100 (88.8–100)
T18: 98.9 (97.1–99.7)
T13: 98.4 (96.4–99.4)
...................................................................................................................................................................................
39 (39) 100 (92–100) 99.7 (98.8–99.9)
...................................................................................................................................................................................
97)
98)
(106)
T21: 11 (11)
T18: 10 (10)
T13: 2 (2)
T21: 100 (76.2–100)
T18: 100 (74.5–100)
T13: 100 (22.4–100)
T21: 100 (97–100)
T18: 100 (97–100)
T13: 100 (97.2–100)
...................................................................................................................................................................................
86 (68) 79.1 (70.6–86) 98.9 (97.9–99.5)
...................................................................................................................................................................................
86 (86) 100 (96.6–100) 97.9 (94.8–99.8)
...................................................................................................................................................................................
212 (209) 98.6 (96.4–99.6) 99.8 (99.5–99.9)
...................................................................................................................................................................................
T21: 36 (36)
T18: 8 (8)
T21: 100 (92.1–100)
T18: 100 (68.8–100)
T21: 100 (97.6–100)
T18: 100 (97.6–100)
...................................................................................................................................................................................
T21: 50 (50)
T18: 50 (49)
T21: 100 (94.2–100)
T18: 98 (90.1–99.9)
T21: 100 (99–100)
T18: 100 (99–100)
...................................................................................................................................................................................
lel sequencing; RT, reverse transcriptase; SNP, single nucleotide polymorphisms; T, trisomy.
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www.AJOG.org Editorialstein A and human chorionic gonadotrophin), as it offers im-
proved detection rates with fewer false-positive results than
second-trimester serum screening.34 Those women with a
iven risk, in theUnitedKingdom it is1:150, are then offered
nvasive tests for definitive diagnosis. There is also increasing
vidence that the combined test screens for other complica-
ions of pregnancy including preeclampsia,35,36 intrauterine
growth restriction,37,38 cardiac anomalies,39,40 and other anom-
alies andgenetic syndromes.41-43 Furthermore, ultrasoundwill be
required in the delivery of any test based on cffDNA, be it screen-
ing or diagnostic, as it will be necessary to confirm the gestational
age and number of fetuses present to perform the test and inter-
pret results. Given these observations, in countries such as the
United Kingdom with well-established national screening pro-
grams, we must question whether any new test for DS should
replace current screening tests. The alternative would be to use
NIPD in conjunctionwith current screening, either to replace in-
vasive testing or as a form of contingent screening, or in addition
to the current screening tests. Given the economic constraints we
face worldwide, the latter approach seems unlikely, but to aban-
donnuchal translucency,pregnancy-associatedplasmaproteinA,
andhumanchorionicgonadotrophinmeasurementand theirpo-
tential benefits if programs are alreadywell established also seems
foolhardy.
Economic considerations
The relative cost of NIPD and invasive prenatal diagnosis
(IPD) is likely to be an important factor in deciding how we
implement NIPD, especially in cash-constrained publicly
fundedhealth care systems. The total cost of includingNIPD in
the DS diagnostic pathway depends on the cost of NIPD test-
ing, numbers undergoing NIPD (a function of the propensity
to offer diagnostic tests), and the accuracy of NIPD (because
thismay affect the use of confirmatory IPD testing). The cost of
NIPD testing is likely to vary by country, and will probably
TABLE 2
Projected numbers undergoing noninvasive prenatal d
Screening NIPD
Cut-off (1 in) DRS FPRS NIPD DRN
150 85.0% 2.5% 13,646 99.0%
....................................................................................................................................................................................
500 94.0% 7% 37,704 99.0%
....................................................................................................................................................................................
1000 96.0% 12% 60,668 99.0%
....................................................................................................................................................................................
2000 98.0% 19% 94,103 99.0%
....................................................................................................................................................................................
5000 99.0% 31% 155,944 99.0%
....................................................................................................................................................................................
10,000 99.5% 43% 215,785 99.0%
....................................................................................................................................................................................
Figures calculated for hypothetical population of 500,000 women. With Down syndrome prevalen
rather than NIPD with screening cut-off of 1 in 150, 13,646 women would undergo CVS, detecti
CVS, chorionic villus sampling; DRN, detection rate with NIPD; DRS, detection rate with screening
prevalence cases – TPN; FPN, false-positive results with NIPD; FPRN, false-positive rate with NIPD;
with NIPD.
Chitty. Noninvasive prenatal testing for aneuploidy. Am J Obstet Gynecol 2012.decrease over time. The number undergoing NIPD will also ivary by country, depending on screening policy and practice,
but the accuracy of NIPD should be the same across countries,
and will probably increase over time.
We chose to look at the costs of introducing NIPD in the
United Kingdom as it is a publicly funded health care system
with a well-defined care pathway where all pregnant women
are offered screening for DS. The modeling is based on United
Kingdom costs and estimated prevalence of DS in our popula-
tion. We calculated the impact of introducing NIPD into the
DS diagnostic pathway assuming that all high-risk women
identified by screening would undergo NIPD, and that those
with a positive NIPD would undergo confirmatory IPD. For
the purposes of this commentary we have modeled costs based
on a first-trimester screening program and used costs associ-
ated with chorionic villus sampling (CVS). Where possible we
have used published cost data44 or data obtained from local
ospitals.7 As mentioned above, these costs will change with
time, and between countries.We assumeDSprevalence at time
of screening of 1 in 360,45 so that in a hypothetical cohort of
00,000 pregnant women 1389 will have an affected fetus. Us-
ng a screening cut-off of 1 in 150 (the currentUnitedKingdom
tandard) 13,646 women would undergo NIPD (Table 2). For
he purposes of this discussionwehave used a detection rate for
IPD of 99% and a false-positive rate of 1%. This is based on
he data from the large studies recently reported.8,9,28 Using
hese figures, 1305 of these women would subsequently un-
ergoCVS,with 13miscarriages, and 1169DS cases detected. If
e assumed a cost per NIPD test of £200 the total cost of
creening and diagnosis would be £29.7 million (Table 3).
Using IPD rather than NIPD with the same screening cut-
ff, 13,646 women would undergo CVS with an estimated 136
iscarriages and 1181 cases detected. The projected total cost
ould be £31.8 million if aneuploidy exclusion alone was per-
ormed. Hence, with a cost per test of £200, a detection rate of
9%, and a false-positive rate of 1%, given the errors inherent
nosis
CVS
RN TPN FPN FNSN CVS Miscarriages
% 1169 136 220 1305 13
...................................................................................................................................................................................
% 1293 377 96 1670 17
...................................................................................................................................................................................
% 1320 607 69 1927 19
...................................................................................................................................................................................
% 1348 941 41 2289 23
...................................................................................................................................................................................
% 1361 1559 28 2921 29
...................................................................................................................................................................................
% 1368 2158 21 3526 35
...................................................................................................................................................................................
screening of 1 in 360 number of affected fetuses is 1389. Using invasive prenatal diagnosis
81 Down syndrome prevalence cases with estimated 136 miscarriages.
N, combined false-negative results with screening and NIPD number of Down syndrome
S, false-positive rate with screening; NIPD, noninvasive prenatal diagnosis; TPN, true positivesiag
FP
1.0
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Editorials www.AJOG.orgwithNIPD there will be fewer procedural-related losses of nor-
mal pregnancies and 12 fewer DS cases detected. If the cost per
NIPD cost was higher or lower than £200 then this would affect
the total cost (Table 3).
If the screening cut-off increased so that more women were
offered NIPD, more DS cases would be detected but costs
would increase. For example, using a screening cut-off of 1 in
2000 the screening detection rate would increase to 98%,
around 94,000 women would undergo NIPD, and 1348 DS
cases would be detected. The total cost would be £46.2 million
if the cost perNIPD testwere £200. If the cost perNIPD testwas
£50 then the total cost would be similar to the total cost of IPD
based on a screening cut-off of 1 in 150,with 167moreDS cases
detected and fewer miscarriages.
If we abandoned the current DS screening programs and
offered NIPD to all women, then at a cost of £50, NIPD would
be as cheap as or cheaper than the contingent screening de-
scribed above, since the cost ofDS screeningwould be avoided,
although an ultrasound scan would still be required to date the
pregnancy.NIPD instead of screeningwould detect a high pro-
portion of cases of trisomy 21 (99%, or 1375 cases). However,
with a false-positive rate of 1%, around 6300 confirmatory
CVS would be required, half the number required using IPD
with a screening cut-off of 1 in 150.
Hence, depending on NIPD accuracy, trade-offs between
uptake/screening cut-off and cost per test are possible, such
thatNIPD compares favorablywith IPD in terms of costs, cases
detected, and numbers of miscarriages. If the data reported in
the small series described in this journal are confirmed in larger-
scale studies, and sensitivity and specificity approach 100%,
then these estimates will change, as indeed will the cost impli-
cations ifmorewomen chose to accept screening and diagnosis
with the widespread adoption of a safer diagnostic test.
At present, the debate over where these new tests fit in the
antenatal care pathway is largely academic. Evaluation to date
TABLE 3
Projected costs of noninvasive prenatal diagnosis
Screening cut-off
(1 in)
Cost of screening
(£)
Cost of CVS
(£)
Cost/NIPD tes
Cost of NIPD
(£)
150 26,500,000 503,810 6,822,917
....................................................................................................................................................................................
500 26,500,000 644,443 18,852,083
....................................................................................................................................................................................
1000 26,500,000 743,699 30,334,028
....................................................................................................................................................................................
2000 26,500,000 883,372 47,051,389
....................................................................................................................................................................................
5000 26,500,000 1,127,388 77,972,222
....................................................................................................................................................................................
10,000 26,500,000 1,361,025 107,892,361
....................................................................................................................................................................................
Figures calculated for hypothetical population of 500,000 women, based on calculations in Table
women with positive NIPD result would undergo CVS. Total cost cost screening cost CVS
projected total cost would be £26,500,000 £5,267,292 £31,767,292.
CVS, chorionic villus sampling; NIPD, noninvasive prenatal diagnosis.
Chitty. Noninvasive prenatal testing for aneuploidy. Am J Obstet Gynecol 2012.has only been performed in high-risk populations and the
272 American Journal of Obstetrics& Gynecology APRIL 2012small false-positive rate reported in the recent validation stud-
ies of NIPD forDSmeans that confirmation by invasive testing
is required. As such the NIPD test can only be regarded as an
“advanced screening test.”12 Also of concern is the possibility
f false-negative results. Data from current studies suggest
alse-negative rates are low; however, these studies have rela-
ively small numbers of cases and have been conducted in the
igh-risk populations using samples from women who are at
ncreased risk following DS screening. Much larger studies are
equired to accurately estimate the test specificity and itmay be
hat implementation with close monitoring of pregnancy out-
omes will be required to obtain true estimates of accuracy. In
ddition, it is not yet clear what the gestational limits of the test
ill be and this is a key factor in guiding where NIPD sits in the
ntenatal care pathway, although the data presented here by
shoor et al15 focus on the first trimester.
Although holding off on widespread implementation until
ccuracy is nearly perfect may be the ideal held by health pro-
essionals, it may not in fact reflect women’s values and needs.
ealth providers may hold different values from patients with
espect to test attributes for DS screening.46 It would seem that
opinions on NIPD also vary. Preliminary analysis of data col-
lected in a discrete choice study comparing opinions of obste-
tricians and midwives with those of pregnant women in the
United Kingdom clearly shows that, although both groups
value safety and accuracy, women are prepared to accept re-
duced accuracy for greater safety, unlike the professionals who
rate accuracy highest. Similarly in aUS studyof pregnantwom-
en’s opinions and interest in NIPD for DS the majority of
women (75%) rated safety the most important factor of NIPD
followed by accuracy (13%) or early results (7%).47
The extent of diagnosis
Implementation clearly has the potential to decrease the rate of
£500 Cost/NIPD test  £200 Cost/NIPD test  £50
tal cost
)
Cost of NIPD
(£)
Total cost
(£)
Cost of NIPD
(£)
Total cost
(£)
3,826,727 2,729,167 29,732,977 682,292 27,686,102
...................................................................................................................................................................................
5,996,526 7,540,833 34,685,276 1,885,208 29,029,651
...................................................................................................................................................................................
7,577,726 12,133,611 39,377,310 3,033,403 30,277,101
...................................................................................................................................................................................
4,434,761 18,820,556 46,203,927 4,705,139 32,088,511
...................................................................................................................................................................................
5,599,610 31,188,889 58,816,277 7,797,222 35,424,610
...................................................................................................................................................................................
5,753,386 43,156,944 71,017,970 10,789,236 38,650,261
...................................................................................................................................................................................
st of screening £53.43 Cost of CVS £386.7 Cost of NIPD varied in table. We assume all
t NIPD. Using invasive prenatal diagnosis rather than NIPD with screening cut-off of 1 in 150,t 
To
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www.AJOG.org EditorialsNIPD for trisomy 21, although the data presented in the papers
reported here include targets for trisomy 18, and others have
explored the detection of the other major trisomies (Table 1).
First-trimester screening algorithms increasingly include de-
tection of trisomies 13 and 18,48-50 and if full karyotyping is
erformed rather than rapid aneuploidy exclusion using fluo-
escence in situ hybridization or real-time-polymerase chain
eaction, other chromosomal rearrangements with a high risk
f adverse outcome are also detected in current service delivery
odels that include full karyotyping. Furthermore, the advent
f detailedmolecular karyotyping usingmultiplex ligation-de-
endent probe amplification or microarrays offers the poten-
ial for the prenatal detection of microdeletion syndromes and
ther pathogenic copy number variants conferring a high risk
f adverse outcome.51,52 Our calculations have explored the
osts andoutcomes associatedwithNIPD followingDS screen-
ng. If NIPD were to be implemented with the resultant de-
rease in invasive tests, there is some evidence that it would
etect more DS cases and result in fewer miscarriages, but it
ould also detect fewer nontrisomy 21 chromosomal abnor-
alities. Although it seems likely that NIPD will be refined to
nclude detection of the other major trisomies in the near fu-
ure, techniques for the identification of other pathogenic re-
rrangements may take longer to develop. Prenatal diagnosis
rogramsmay need to include the option of invasive testing in
hose pregnancies where NIPD is normal but the fetus has an
ncreased nuchal translucency or other structural abnormality,
s it is well recognized that this is the groupmost likely to have
ther chromosomal rearrangements.53,54 The impact on costs
n this setting will depend on the relative costs of NIPD, DS
creening, and number of invasive tests performed.
Counseling and ethical issues
Exploration of the ethical and psychosocial issues associated
with implementingNIPD has highlighted several concerns, in-
cluding the potential to undermine informed consent, in-
creased societal pressure to test and terminate affected preg-
nancies, and equity of access.55-57 The small number of studies
valuating stakeholder perceptionof the potential forNIPD for
S suggest a positive response to NIPD overall, but there is
ome unease about the potential negatives.46,58-61 One of the
most debated issues regarding NIPD has been how best to en-
sure informed consent as there is concern that womenmay not
give NIPD sufficient consideration because it will require “just
a blood test.”55-57 This is an ongoing problem for DS testing in
general, as evidence from research on women’s decision mak-
ing for DS screening indicate that women do not always make
informed decisions when taking up DS screening,62 or indeed
are not fully aware of what screening tests they have had.63
Further concerns relate to the potential for increased societal
pressure for testing and termination as tests become safer and
easier to access;59-61 this includes pressure from commercial
nd insurance sectors thatmight perceive economic benefits in
ecreasing the prevalence of disorders.64How NIPD is introduced in the screening and diagnostic
pathway also has the potential to impact on informed consent.
One of the key reasons women decline prenatal screening and
diagnosis for DS is the risk of miscarriage.65 Currently the
-step process of screening and diagnosis and the risk of mis-
arriage associated with diagnostic tests are thought to be psy-
hological barriers to diagnostic testing that prompt women to
hink carefully about their options, and health professionals to
rovide information aimed at facilitating informed choice. If
he miscarriage risk is removed, women may feel less justified
n the decisionnot to have a test;66 theymay give less thought to
these tests and health professionals may give less information
and be less concerned about obtaining informed consent.67
However, incorporation of NIPD into the screening pathway
in conjunction with current screening as described above
would preserve the 2-step process and at least offer the oppor-
tunity to focus on the possible outcomes thatmight arise albeit
from a blood test rather than an invasive one.
Consequently, amajor factor for the successful introduction of
NIPD into routine antenatal care will be the development of ap-
proaches to counseling and strategies for information provision
that will facilitate informed decision making. Key to this will be
provision of education strategies to allow health professionals to
become confident and capable of offering information and non-
directive counseling about the test. A recent survey of obstetric
health professionals from the United States found they were not
secure in their current knowledge of NIPD.61 Moreover, in the
UnitedKingdomit seemsthathealthprofessionalsconsiderNIPD
tobemore like currentDS screening than invasivediagnostic test-
ing in terms of the need for written consent and performing the
test on the same day it is offered.67
Commercial considerations
So far as we are aware at the moment, NIPD for aneuploidy is
only being offered through commercial providers. Access to
the tests and costs are unclear, but seem to require referral via
a physician who will be responsible for discussing results with
women.One issue that could impede progress and the freedom
to operate regards intellectual property rights. The prenatal
diagnosismarket is highly lucrative, therefore, understandably,
commercial providers see NIPD as a major opportunity and
are keen to capture the market. Although one company claims
to hold all intellectual property rights for this testing, there are
now several lawsuits in progress; undoubtedly, the patent land-
scape is complex and we can anticipate protracted suits and
countersuits as the technology continues to develop and be
implemented. From the patient’s perspective, it is critical that
access to testing is not restricted or curtailed as a result of pat-
ent enforcement. Further, hopefully commercial companies
do not restrict access by pricing NIPD out of the market for
widespread use, which might be a particular problem in pub-
licly funded systems with fixed budgets.
These tests also lend themselves to direct-to-consumermar-
keting. Although this does not appear to be happening at the
moment, at least for aneuploidy testing, it can cause difficulties
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difficult to ensure test accuracy, reliability, informed consent,
or access.55,68 Notably, research into public attitudes identified
oncerns that people having NIPD outside a clinical setting
ould not receive sufficient support and counseling60 and a
survey of health professionals in the United States found they
did not support direct-to-consumer testing.61
Conclusions
Thepaperspublishedhere arenodoubtonly thefirst ofmany that
will be seen this year describing potential approaches for delivery
of NIPD. However, there is a long way to go yet before we see
widespread implementation of NIPD for aneuploidy, but if we
consider the pace of developments over the last couple of years,
this may occur faster than anticipated. These new approaches
must be evaluated in the appropriate populations, but in parallel
we must develop health professional and patient education re-
garding limitations of the tests and the implications of results.
High-quality pretest counseling to enable informed parental
choice has always been a prerequisite of antenatal screening. Re-
moval of the barriers caused by risk of miscarriage makes coun-
seling an even more important feature of any service offering
NIPD.Healthservicesneedtorespondrapidly todevelopments to
avoidpatchyaccessvia thecommercial sector resulting in inequal-
ity of access formanywomen. The ultimate aimmust be for plat-
forms that are robust, lend themselves to high throughput with
rapid turnaround times, and are cost-efficient. Whether this will
be a sequencing platform, digital polymerase chain reaction, or
another approach remains to be seen.Whatever platform is used,
if this technology is to be applied to all women seeking antenatal
care then thenext steps are to establish largeprospective studies of
low-risk populations where all aspects are considered, including
test performance, turnaround times, counseling requirements,
and economic aspects. Finally, it is to be hoped that the issues
around intellectual property rights are resolved promptly and do
not impede implementationof technology thatwill clearly benefit
families by delivering a test to those requesting screening that
avoids the loss of normal pregnancies.
These developments in the field of NIPD are exciting and
promise positive changes for prenatal care. With the knowl-
edge that the introduction of NIPD into clinical practice for
fetal sex determination has already reduced the need for inva-
sive testing forwomen at risk of sex-linked conditions, we hope
that this success will extend to other indications for NIPD,
including DS, in the near future. f
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